|
|
|
|
|
|
by benchtobedside
605 days ago
|
|
|
Another interesting point from the study (full paper linked in a other comment) was the comparison of semaglutide to other GLP-1 agonists taken by patients, with the impact being significantly higher vs. those. Obviously we need some more double blind studies dedicated to this class of drugs and Alzheimer's, but this informs the direction researchers and drug companies will likely map out. |
|
|